Primary Objective:~To evaluate the safety of sarilumab cemiplimab combination in metastatic lung cancer patients.~The primary endpoint is DLT for safety Run-In cohort.~To preliminarily assess efficacy of sarilumab cemiplimab combination in patients with EGFR- or LKB1/STK11-mutant NSCLC respectively.~The primary efficacy endpoint is objective response rate (ORR) in cohort A and cohort B, evaluated separately.~Secondary Objectives:~--To evaluate the progression-free survival (PFS), disease control rate (DOR), duration of response (DoR), overall survival (OS), and safety and tolerability of this combination in patients with EGFR- or LKB1-mutant NSCLC respectively.~Correlative/Exploratory Objectives:~Explore the association of baseline genomic profiles (from tumor, germline DNA, and ctDNA) with clinical benefit in patients treated with sarilumab and cemiplimab combination~Explore the association of immune profiles (tumor immune microenvironment features) with clinical benefit in patients treated with sarilumab and cemiplimab combination~Explore resistance mechanisms to sarilumab and cemiplimab combination.~Determine the impact of sarilumab on immunotherapy-related side effects from cemiplimab.
To learn if the combination of sarilumab (also called Kevzara) and cemiplimab can help to control EGFR- or LKB1/STK11-mutant NSCLC.